Altimmune with ticker code (ALT) have now 7 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 30 and 12 with a mean TP of 23.14. With the stocks previous close at 13.12 this is indicating there is a potential upside of 76.4%. The 50 day MA is 8.5 while the 200 day moving average is 8.32. The company has a market capitalisation of $565m. Company Website: https://altimmune.com
The potential market cap would be $997m based on the market concensus.
Altimmune, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company’s lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune in September 2015. Altimmune was founded in 1997 is headquartered in Gaithersburg, Maryland.
